Literature DB >> 19969019

Endocannabinoid signaling in neurotoxicity and neuroprotection.

C Pope1, R Mechoulam, L Parsons.   

Abstract

The cannabis plant and products produced from it, such as marijuana and hashish, have been used for centuries for their psychoactive properties. The mechanism for how Delta(9)-tetrahydrocannabinol (THC), the active constituent of cannabis, elicits these neurological effects remained elusive until relatively recently, when specific G-protein coupled receptors were discovered that appeared to mediate cellular actions of THC. Shortly after discovery of these specific receptors, endogenous ligands (endocannabinoids) were identified. Since that time, an extensive number of papers have been published on the endocannabinoid signaling system, a widespread neuromodulatory mechanism that influences neurotransmission throughout the nervous system. This paper summarizes presentations given at the 12th International Neurotoxicology Association meeting that described the potential role of endocannabinoids in the expression of neurotoxicity. Dr. Raphael Mechoulam first gave an overview of the discovery of exogenous and endogenous cannabinoids and their potential for neuroprotection in a variety of conditions. Dr. Larry Parsons then described studies suggesting that endocannabinoid signaling may play a selective role in drug reinforcement. Dr. Carey Pope presented information on the role that endocannabinoid signaling may have in the expression of cholinergic toxicity following anticholinesterase exposures. Together, these presentations highlighted the diverse types of neurological insults that may be modulated by endocannabinoids and drugs/toxicants which might influence endocannabinoid signaling pathways.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969019      PMCID: PMC2891218          DOI: 10.1016/j.neuro.2009.12.002

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  145 in total

Review 1.  Endocannabinoids in liver disease and hepatic encephalopathy.

Authors:  Iddo Magen; Yosefa Avraham; Elliot Berry; Raphael Mechoulam
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 2.  Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation.

Authors:  Sachin Patel; Cecilia J Hillard
Journal:  Eur J Neurosci       Date:  2008-06       Impact factor: 3.386

Review 3.  Serine hydrolase targets of organophosphorus toxicants.

Authors:  John E Casida; Gary B Quistad
Journal:  Chem Biol Interact       Date:  2005-10-21       Impact factor: 5.192

4.  Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice.

Authors:  Gary B Quistad; Rebecka Klintenberg; Pierluigi Caboni; Shannon N Liang; John E Casida
Journal:  Toxicol Appl Pharmacol       Date:  2005-11-28       Impact factor: 4.219

5.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.

Authors:  D Panikashvili; C Simeonidou; S Ben-Shabat; L Hanus; A Breuer; R Mechoulam; E Shohami
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

Review 6.  Alcoholism: allostasis and beyond.

Authors:  George F Koob
Journal:  Alcohol Clin Exp Res       Date:  2003-02       Impact factor: 3.455

7.  Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

8.  Brain monoglyceride lipase participating in endocannabinoid inactivation.

Authors:  T P Dinh; D Carpenter; F M Leslie; T F Freund; I Katona; S L Sensi; S Kathuria; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

9.  Enantiomeric cannabinoids: stereospecificity of psychotropic activity.

Authors:  R Mechoulam; J J Feigenbaum; N Lander; M Segal; T U Järbe; A J Hiltunen; P Consroe
Journal:  Experientia       Date:  1988-09-15

10.  Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats.

Authors:  Zheng-Xiong Xi; Krista Spiller; Arlene C Pak; Jeremy Gilbert; Christopher Dillon; Xia Li; Xiao-Qing Peng; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2007-08-29       Impact factor: 7.853

View more
  11 in total

1.  Comparative effects of chlorpyrifos in wild type and cannabinoid Cb1 receptor knockout mice.

Authors:  Praveena Baireddy; Jing Liu; Myron Hinsdale; Carey Pope
Journal:  Toxicol Appl Pharmacol       Date:  2011-06-13       Impact factor: 4.219

Review 2.  Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Authors:  P Pacher; R Mechoulam
Journal:  Prog Lipid Res       Date:  2011-02-02       Impact factor: 16.195

3.  Preliminary evidence for white matter metabolite differences in marijuana-dependent young men using 2D J-resolved magnetic resonance spectroscopic imaging at 4 Tesla.

Authors:  Marisa M Silveri; John Eric Jensen; Isabelle M Rosso; Jennifer T Sneider; Deborah A Yurgelun-Todd
Journal:  Psychiatry Res       Date:  2011-03-31       Impact factor: 3.222

4.  Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use.

Authors:  Rebecca C Hanna; Alexandra Shalvoy; C Munro Cullum; Elena I Ivleva; Matcheri Keshavan; Godfrey Pearlson; S Kristian Hill; John A Sweeney; Carol A Tamminga; Subroto Ghose
Journal:  Schizophr Bull       Date:  2016-03-31       Impact factor: 9.306

5.  Comparative effects of parathion and chlorpyrifos on extracellular endocannabinoid levels in rat hippocampus: influence on cholinergic toxicity.

Authors:  Jing Liu; Loren Parsons; Carey Pope
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-07       Impact factor: 4.219

6.  Cortical thickness and neurocognition in adolescent marijuana and alcohol users following 28 days of monitored abstinence.

Authors:  Joanna Jacobus; Lindsay M Squeglia; Scott F Sorg; Tam T Nguyen-Louie; Susan F Tapert
Journal:  J Stud Alcohol Drugs       Date:  2014-09       Impact factor: 2.582

7.  Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana.

Authors:  Young-Hoon Sung; Paul D Carey; Dan J Stein; Helen L Ferrett; Bruce S Spottiswoode; Perry F Renshaw; Deborah A Yurgelun-Todd
Journal:  Behav Brain Res       Date:  2013-03-04       Impact factor: 3.332

8.  Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity.

Authors:  M Paola Castelli; Camilla Madeddu; Alberto Casti; Angelo Casu; Paola Casti; Maria Scherma; Liana Fattore; Paola Fadda; M Grazia Ennas
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

Review 9.  Safety and Toxicology of Cannabinoids.

Authors:  Jane Sachs; Erin McGlade; Deborah Yurgelun-Todd
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  The neuropsychopharmacology of cannabis: A review of human imaging studies.

Authors:  Michael A P Bloomfield; Chandni Hindocha; Sebastian F Green; Matthew B Wall; Rachel Lees; Katherine Petrilli; Harry Costello; M Olabisi Ogunbiyi; Matthijs G Bossong; Tom P Freeman
Journal:  Pharmacol Ther       Date:  2018-10-19       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.